Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 2
2010 5
2011 5
2012 7
2013 7
2014 4
2015 1
2016 6
2017 3
2018 2
2019 3
2020 2
2021 5
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Multidisciplinary approach to prostatitis.
Magri V, Boltri M, Cai T, Colombo R, Cuzzocrea S, De Visschere P, Giuberti R, Granatieri CM, Latino MA, Larganà G, Leli C, Maierna G, Marchese V, Massa E, Matteelli A, Montanari E, Morgia G, Naber KG, Papadouli V, Perletti G, Rekleiti N, Russo GI, Sensini A, Stamatiou K, Trinchieri A, Wagenlehner FME. Magri V, et al. Among authors: leli c. Arch Ital Urol Androl. 2019 Jan 18;90(4):227-248. doi: 10.4081/aiua.2018.4.227. Arch Ital Urol Androl. 2019. PMID: 30655633 Free article.
The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors.
Sottotetti F, Ferraris E, Tagliaferri B, Palumbo R, Quaquarini E, Teragni C, Balletti E, Leli C, Premoli A, Mollica L, Puglisi S, Sardi S, Malovini A, Pedrazzoli P, Bernardo A. Sottotetti F, et al. Among authors: leli c. Drugs Context. 2022 Sep 5;11:2022-1-3. doi: 10.7573/dic.2022-1-3. eCollection 2022. Drugs Context. 2022. PMID: 36118250 Free PMC article.
Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR+/HER2- breast cancer treated with CDK4/6 inhibitors and endocrine therapy.
Tagliaferri B, Mollica L, Palumbo R, Leli C, Malovini A, Terzaghi M, Quaquarini E, Teragni C, Maccarone S, Premoli A, Sottotetti F. Tagliaferri B, et al. Among authors: leli c. Drugs Context. 2023 Jun 20;12:2023-1-7. doi: 10.7573/dic.2023-1-7. eCollection 2023. Drugs Context. 2023. PMID: 37378079 Free PMC article.
49 results